87 related articles for article (PubMed ID: 20602622)
21. [Efficacy of rituximab-containing regimens on indolent B-cell lymphoma--a report of 34 cases].
Xia ZJ; Wang FH; Huang HQ; Luo HY; Li YH; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):490-4. PubMed ID: 16613687
[TBL] [Abstract][Full Text] [Related]
22. Severe thrombocytopenia induced by a single infusion of trastuzumab.
Parikh O; Neave F; Palmieri C
Clin Breast Cancer; 2008 Jun; 8(3):285-6. PubMed ID: 18650161
[TBL] [Abstract][Full Text] [Related]
23. Immune thrombocytopenia induced by fludarabine successfully treated with rituximab.
Fernandez MJ; Llopis I; Pastor E; Real E; Grau E
Haematologica; 2003 Feb; 88(2):ELT02. PubMed ID: 12604433
[No Abstract] [Full Text] [Related]
24. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma.
Robinson KS; Williams ME; van der Jagt RH; Cohen P; Herst JA; Tulpule A; Schwartzberg LS; Lemieux B; Cheson BD
J Clin Oncol; 2008 Sep; 26(27):4473-9. PubMed ID: 18626004
[TBL] [Abstract][Full Text] [Related]
25. Cytomegalovirus-associated meningoradiculoneuritis after treatment of mantle cell lymphoma with a combination of chemotherapy and rituximab.
Vallet S; Tempescul A; Tran A; Legrand-Quillien MC; Narbonne V; Berthou C
Ann Hematol; 2005 Aug; 84(8):545-7. PubMed ID: 15789227
[No Abstract] [Full Text] [Related]
26. Acute intracerebral hemorrhage in intravascular lymphoma: a serious infusion related adverse event of rituximab.
Ganguly S
Am J Clin Oncol; 2007 Apr; 30(2):211-2. PubMed ID: 17414473
[No Abstract] [Full Text] [Related]
27. Fulminant hepatitis B following rituximab therapy in a patient with Evans syndrome and large B-cell lymphoma.
Ozgönenel B; Moonka D; Savaşan S
Am J Hematol; 2006 Apr; 81(4):302. PubMed ID: 16550511
[No Abstract] [Full Text] [Related]
28. Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma.
Robak T; Smolewski P; Cebula B; Szmigielska-Kaplon A; Chojnowski K; Blonski JZ
Cancer; 2006 Oct; 107(7):1542-50. PubMed ID: 16948126
[TBL] [Abstract][Full Text] [Related]
29. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma.
Rummel MJ; Al-Batran SE; Kim SZ; Welslau M; Hecker R; Kofahl-Krause D; Josten KM; Dürk H; Rost A; Neise M; von Grünhagen U; Chow KU; Hansmann ML; Hoelzer D; Mitrou PS
J Clin Oncol; 2005 May; 23(15):3383-9. PubMed ID: 15908650
[TBL] [Abstract][Full Text] [Related]
30. Enteroviral meningoencephalitis after anti-CD20 (rituximab) treatment.
Quartier P; Tournilhac O; Archimbaud C; Lazaro L; Chaleteix C; Millet P; Peigue-Lafeuille H; Blanche S; Fischer A; Casanova JL; Travade P; Tardieu M
Clin Infect Dis; 2003 Feb; 36(3):e47-9. PubMed ID: 12539090
[TBL] [Abstract][Full Text] [Related]
31. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK).
Ghielmini M; Schmitz SF; Cogliatti S; Bertoni F; Waltzer U; Fey MF; Betticher DC; Schefer H; Pichert G; Stahel R; Ketterer N; Bargetzi M; Cerny T;
J Clin Oncol; 2005 Feb; 23(4):705-11. PubMed ID: 15598978
[TBL] [Abstract][Full Text] [Related]
32. Remarkable response to rituximab in a patient with atypical CD20(++) mantle cell lymphoma of the bone marrow leading to severe pancytopenia.
Seggewiss R; Ho AD; Kraemer A
Ann Hematol; 2004 May; 83(5):316-8. PubMed ID: 15064861
[TBL] [Abstract][Full Text] [Related]
33. [Rituximab, a chimeric anti-CD20 monoclonal antibody, in the treatment of B-cell lymphoma].
Tobinai K
Gan To Kagaku Ryoho; 2002 Mar; 29(3):473-80. PubMed ID: 11915743
[TBL] [Abstract][Full Text] [Related]
34. Activity and safety of combined rituximab with chlorambucil in patients with mantle cell lymphoma.
Bauwens D; Maerevoet M; Michaux L; Théate I; Hagemeijer A; Stul M; Danse E; Costantini S; Vannuffel P; Straetmans N; Vekemans MC; Deneys V; Ferrant A; Van Den Neste E
Br J Haematol; 2005 Nov; 131(3):338-40. PubMed ID: 16225653
[TBL] [Abstract][Full Text] [Related]
35. [Disappearance of CD 20 after treatment with rituximab of mantle cell lymphoma].
Yoshida K; Kayano H; Shimada T; Wakao D; Takahashi N; Sugahara Y; Yagasaki F; Ito Y; Kawai N; Matsuda A; Suzuki T; Bessho M
Rinsho Ketsueki; 2003 Mar; 44(3):174-81. PubMed ID: 12722344
[TBL] [Abstract][Full Text] [Related]
36. Intraperitoneal application of rituximab in refractory mantle cell lymphoma with massive ascites resulting in local and systemic response.
Crysandt M; Neumann B; Das M; Engelbertz V; Bendel M; Galm O; Osieka R; Jost E
Eur J Haematol; 2007 Dec; 79(6):546-9. PubMed ID: 17903214
[TBL] [Abstract][Full Text] [Related]
37. Hyperacute pulmonary edema complicating rituximab infusion.
Chan KH; Ng MK
Eur J Intern Med; 2009 Jan; 20(1):e13. PubMed ID: 19237066
[No Abstract] [Full Text] [Related]
38. Fludarabine, Bortezomib, Myocet and rituximab chemotherapy in relapsed and refractory mantle cell lymphoma.
Orciuolo E; Buda G; Pelosini M; Petrini M
Br J Haematol; 2010 Mar; 148(5):810-2. PubMed ID: 19919649
[No Abstract] [Full Text] [Related]
39. [Maintenance therapy with rituximab].
Krankenpfl J; 2005; 43(7-10):222-4. PubMed ID: 16515293
[No Abstract] [Full Text] [Related]
40. [Increased response rate with rituximab in relapsed and refractory follicular and mantle cell lymphomas -- results of a prospective randomized study of the German Low-Grade Lymphoma Study Group].
Forstpointner R; Hänel A; Repp R; Hermann S; Metzner B; Pott C; Hartmann F; Rothmann F; Böck HP; Wandt H; Unterhalt M; Hiddemann W
Dtsch Med Wochenschr; 2002 Oct; 127(43):2253-8. PubMed ID: 12397539
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]